These ECVs, which provide some context for interpreting an MIC value, are an additional tool in selecting antifungal therapy while also considering factors such as pharmacokinetics and pharmacodynamics, site of infection, lesion size, and patient’s health status (e.g., CARD9 mutations) (4, 25). The gene discussed is CARD9; the disease is infection.